 "Dr Reddy’s Laboratories likely to launch Sputnik V under EUA in March")
Dr Reddy’s Laboratories (DRL) plans to apply for emergency use approval (EUA) for the Russian Sputnik V from the Indian drug regulator in March and launch the vaccine around the same time.
Meanwhile, DRL is in discussions with the Russian Direct Investment Fund (RDIF) to expand the scope of this partnership on Sputnik to other countries where Hyderabad-based pharma major has strong presence. DRL is partnering RDIF for conducting the clinical trials and would be marketing the Sputnik V in India at present.
The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase
